Radioresistance in carcinoma of the breast

被引:94
作者
Jameel, JKA
Rao, VSR
Cawkwell, L
Drew, PJ [1 ]
机构
[1] Castle Hill Hosp, Acad Surg Unit, Cottingham HU16 5JQ, Yorks, England
[2] Univ Hull, Post Grad Med Inst, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England
关键词
breast cancer; radiotherapy; radioresistance; recurrence;
D O I
10.1016/j.breast.2004.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiotherapy plays an important role in the management of breast cancer. Whilst its role in achieving local control following surgery in patients with early stage cancer is well established, there is still unclear evidence to explain the factors governing radioresistance in patients who develop recurrences both in the breast and axilla. Radiotherapy induces damage to the DNA. Various cell cycle damage check points and DNA damage repair pathways have been demonstrated. Ataxia telangiectasia mutant (ATM) kinase, which is a member of phosphatidylinositol-3 kinase (PI-3K) family appears to play a central role in DNA damage check point pathways. Over-expression of Insulin like growth factor-I receptor (IGF-IR), Human Epidermal Growth factor receptors (HERS), Vascular Endothelial growth factor (VEGF) on the cell surface and increased concentration of Epidermal Growth factor in the extracellular fluid have been associated with radio resistance. Specific genes such as p53, BRCA, Bcl-2 and chromosomal characteristics like telomere lengths have also been identified as playing significant roles in radiation responsiveness of a cell. This article reviews the current data on general principles of radiotherapy, the cellular mechanisms that operate in response to radiation damage and various molecular markers, intranuclear and extranuclear which have been demonstrated to influence radiation sensitivity in breast cancer cells. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:452 / 460
页数:9
相关论文
共 57 条
  • [41] Sartor CI, 2000, SEMIN ONCOL, V27, P15
  • [42] SARTORI CI, 2003, SEMIN RADIAT ONCOL, V89, P189
  • [43] Saugier-Veber P, 1998, HUM MUTAT, V12, P259, DOI 10.1002/(SICI)1098-1004(1998)12:4<259::AID-HUMU7>3.0.CO
  • [44] 2-A
  • [45] A SINGLE ATAXIA-TELANGIECTASIA GENE WITH A PRODUCT SIMILAR TO PI-3 KINASE
    SAVITSKY, K
    BARSHIRA, A
    GILAD, S
    ROTMAN, G
    ZIV, Y
    VANAGAITE, L
    TAGLE, DA
    SMITH, S
    UZIEL, T
    SFEZ, S
    ASHKENAZI, M
    PECKER, I
    FRYDMAN, M
    HARNIK, R
    PATANJALI, SR
    SIMMONS, A
    CLINES, GA
    SARTIEL, A
    GATTI, RA
    CHESSA, L
    SANAL, O
    LAVIN, MF
    JASPERS, NGJ
    MALCOLM, A
    TAYLOR, R
    ARLETT, CF
    MIKI, T
    WEISSMAN, SM
    LOVETT, M
    COLLINS, FS
    SHILOH, Y
    [J]. SCIENCE, 1995, 268 (5218) : 1749 - 1753
  • [46] Shtivelman E, 2003, MOL CANCER RES, V1, P959
  • [47] Prenatal diagnosis of a rhodopsin mutation using chemical cleavage of the mismatch
    Tessitore, A
    Toniato, E
    Gulino, A
    Frati, L
    Ricevuto, E
    Vadalà, M
    Vingolo, E
    Martinotti, S
    [J]. PRENATAL DIAGNOSIS, 2002, 22 (05) : 380 - 384
  • [48] Recognition and management of hereditary breast cancer syndromes
    Thull, DL
    Vogel, VG
    [J]. ONCOLOGIST, 2004, 9 (01) : 13 - 24
  • [49] Turner BC, 1997, CANCER RES, V57, P3079
  • [50] A gene-expression signature as a predictor of survival in breast cancer.
    van de Vijver, MJ
    He, YD
    van 't Veer, LJ
    Dai, H
    Hart, AAM
    Voskuil, DW
    Schreiber, GJ
    Peterse, JL
    Roberts, C
    Marton, MJ
    Parrish, M
    Atsma, D
    Witteveen, A
    Glas, A
    Delahaye, L
    van der Velde, T
    Bartelink, H
    Rodenhuis, S
    Rutgers, ET
    Friend, SH
    Bernards, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) : 1999 - 2009